Neko pivot to health system partnerships

The real upside here is not more clinic revenue, it is turning Neko from a scan provider into infrastructure that health systems can use to find risk earlier across large patient groups. The studies are built around concrete disease pathways, microcirculation, vascular aging, and diabetes complications, and they are running inside a major Swedish research program and hospital setting. That is the kind of evidence base a hospital would need before buying software, devices, or screening workflows at system scale.1 2 3 4

• Neko is already testing this in real clinical environments, with two SCAPIS 2 sub studies and the MIND diabetes study at Danderyd Hospital in Sweden. The work focuses on whether sensor readings and blood markers can catch disease processes before symptoms or organ damage appear.1 2 3
• The path to partnership is operational, not just scientific. Neko says the SCAPIS 2 Cardio study uses contactless laser and microwave radar sensors in a workflow designed to be highly efficient and automatable, which is exactly what a health system needs for broad screening rather than boutique executive checkups.2 5
• A useful comparable is Viz.ai. It sells hospitals software that plugs into care delivery once its models show clinical value, and it reached about $40M of revenue in 2023 with an estimated $1.2B valuation. That shows how validated clinical tools can become enterprise health system products, not just consumer services.6 7 8

If these studies keep producing peer reviewed results, the next step is a shift from selling scans one patient at a time to selling prevention workflows into hospitals and public health systems. That would move Neko closer to a higher leverage model where its sensors, software, and risk models sit inside routine screening and chronic disease prevention programs.2 3 4 6